Differently, the PD1+CD28− T-cell subset, after a substantial rise at NT, did not further increase in the tumor, where its frequency was significantly lower than the CD28+ counterpart (19% vs 29.5%, P = 0.007) (Fig. 3C). This evidence concerns the gene PDCD1 and neoplasm.